On this page
ARHGEF9
Cdc42 guanine nucleotide exchange factor 9
The ARHGEF9 gene provides instructions for a protein crucial in neuronal development and the normal functioning of synapses, influencing conditions like epilepsy and intellectual disability. The ARHGEF9 gene, also known as Cdc42 guanine nucleotide exchange factor 9, encodes a protein essential for brain development and synaptic activity.
ARHGEF9 is located on the long (q) arm of chromosome X, at band Xq11.1. Arm ratio per GRCh38 - banding schematic.
Explore chromosome X in the library →Available at Jeen Health
Clinical tests that include this
Overview
The ARHGEF9 gene encodes a protein that plays a significant role in the developing brain, particularly in the formation and function of synapses, which are the junctions between nerve cells. This gene's product contributes to the regulation of neuronal excitability and the organisation of inhibitory synapses. Changes in ARHGEF9 can disrupt these critical processes, leading to neurological conditions.
The protein is involved in signalling pathways that are vital for maintaining proper brain function. Understanding the ARHGEF9 gene aids in comprehending the underlying mechanisms of certain neurological disorders and may inform future therapeutic approaches.
What the gene does
The protein produced by the ARHGEF9 gene primarily functions as a guanine nucleotide exchange factor (GEF), specifically for the small GTPase Cdc42. This role involves activating Cdc42 by facilitating the exchange of GDP for GTP, which then regulates various cellular processes including cell polarity, migration, and membrane trafficking within neurons. Proper regulation of Cdc42 by ARHGEF9 is particularly important for the establishment and remodelling of dendritic spines, which are crucial for synaptic connectivity and plasticity in the brain.
Beyond its GEF activity, the ARHGEF9 protein interacts with other key synaptic proteins, including gephyrin, which is a major component of inhibitory postsynaptic scaffolds. This interaction is critical for clustering GABAergic (inhibitory) receptors at synapses, thereby regulating the balance between neuronal excitation and inhibition. Disruptions in this balance, often caused by pathogenic variants in ARHGEF9, are implicated in seizure disorders and other neurodevelopmental conditions.
Video: Genetics 101
Chromosome location
The ARHGEF9 gene is located on the short arm of the X chromosome at band Xq11.1. This specific chromosomal location places it within a region that is significant for neuronal development and function. The position on the X chromosome means its inheritance pattern can vary depending on the specific variant and affected individuals.
Protein structure
The ARHGEF9 protein, consisting of 516 amino acids, features several distinct domains critical for its function. At the N-terminus, it contains an SH3 domain (amino acids 8-67), which is often involved in protein-protein interactions and signal transduction. A specific interaction with GPHN occurs within a region spanning amino acids 100-110. Following this, the protein includes a DH (Dbl homology) domain (amino acids 103-287), which is responsible for its guanine nucleotide exchange factor activity. Further along, a PH (Pleckstrin homology) domain (amino acids 318-425) plays a role in membrane localisation and binding to phosphoinositides. The protein also contains a disordered region (amino acids 453-480) toward its C-terminus, which may contribute to its flexibility or interactions with other proteins.
Key variants
Variants in the ARHGEF9 gene can encompass a range of changes, from single nucleotide alterations to larger deletions or duplications. These genetic changes can lead to an altered or non-functional protein, disrupting its critical roles in brain development and synaptic activity. The clinical impact of a specific variant often depends on its exact location within the gene and how severely it affects protein function.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1033C>T | p.Arg345Trp | Pathogenic/Likely pathogenic | ★★☆☆ | Inborn genetic diseases |
c.1115G>A | p.Arg372His | Pathogenic/Likely pathogenic | ★★☆☆ | Developmental and epileptic encephalopathy, 8 |
c.1269G>A | p.Trp423Ter | Pathogenic | ★★☆☆ | Developmental and epileptic encephalopathy, 8 |
c.1306del | p.Glu436fs | Pathogenic | ★★☆☆ | Developmental and epileptic encephalopathy, 8 |
c.332G>A | p.Arg111Gln | Pathogenic/Likely pathogenic | ★★☆☆ | Developmental and epileptic encephalopathy, 8 |
c.556G>A | p.Glu186Lys | Pathogenic/Likely pathogenic | ★★☆☆ | Inborn genetic diseases |
c.582+1G>A | - | Pathogenic/Likely pathogenic | ★★☆☆ | Developmental and epileptic encephalopathy, 8 |
c.775C>T | p.Gln259Ter | Pathogenic | ★★☆☆ | Developmental and epileptic encephalopathy, 8 |
c.886C>T | p.Arg296Ter | Pathogenic | ★★☆☆ | Global developmental delay |
c.890G>A | p.Arg297His | Pathogenic/Likely pathogenic | ★★☆☆ | Inborn genetic diseases |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in the ARHGEF9 gene are associated with several neurodevelopmental disorders, primarily affecting brain function. These conditions can include various forms of epilepsy, characterised by recurrent seizures, and intellectual disability, which involves significant limitations in intellectual functioning and adaptive behaviour. The severity and specific presentation of these conditions can vary among affected individuals.
No disease links recorded for this gene in our reference set.
UK clinical status
The ARHGEF9 gene is part of the NHS Genomic Medicine Service's national gene panels, indicating its clinical relevance within the UK. It is listed on the 'DDG2P' panel, the 'Early onset or syndromic epilepsy' panel (R59), and the 'Intellectual disability' panel (R29). This inclusion signifies that variants in ARHGEF9 are considered when investigating these conditions in a clinical setting.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does the ARHGEF9 gene do?
The ARHGEF9 gene provides instructions for making a protein that acts as a guanine nucleotide exchange factor, primarily activating the protein Cdc42. This process is essential for the healthy development and function of synapses, the connections between nerve cells in the brain.
What conditions are associated with ARHGEF9 gene variants?
Variants in the ARHGEF9 gene are linked to several neurological conditions, including different types of epilepsy, which involve recurrent seizures, and intellectual disability, characterised by challenges in intellectual and adaptive functioning.
Is ARHGEF9 considered in UK clinical genetic testing?
Yes, the ARHGEF9 gene is included in several NHS Genomic Medicine Service national gene panels, specifically for conditions such as early onset or syndromic epilepsy and intellectual disability, meaning it is assessed during clinical genetic investigations for these disorders.